Patent US6028099A successfully refreshed from Google Patents.
US6028099A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
Assignee: Johns Hopkins University
•
Filing: 1998-03-13
•
Granted: 2000-02-22
•
Expires: 2018-03-13
Abstract
Abstract The present invention is directed to a method for the prophylactic and therapeutic treatment of choroidal neovascularization. The method involves the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the choroid for neovascularization prophylactically or therapeutically. The inhibitor of the protein tyrosine kinase pathway is preferably genistein or an analogue or prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing.
Inventors
- 👤 Eugene de Juan, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 06:48
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/35; A61K31/352; A61K31/38; A61K31/382
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
124 words
A method of prophylactically or therapeutically treating an animal for choroidal neovascularization, which method comprises administering to said animal a compound of formula: ##STR3## wherein V, W and X are selected from the group consisting of hydro, alkoxy, hydroxyl, halo, an ester, an ether, a carboxylic acid group, a pharmaceutically acceptable salt of a carboxylic acid group, and --SR, in which R is hydrogen or an alkyl group, and Y is selected from the group consisting of oxygen, sulfur, C(OH), and C═O, and Z is selected from the group consisting of hydro and C(O)OR 1 , wherein R 1 is an alkyl, or a prodrug or pharmaceutically acceptable salt thereof, in an amount sufficient to treat said animal for choroidal neovascularization prophylactically or therapeutically.
Claim 2
Independent Claim
124 words
A method of prophylactically or therapeutically treating an animal for choroidal neovascularization, which method comprises administering to said animal a compound of formula: ##STR3## wherein V, W and X are selected from the group consisting of hydro, alkoxy, hydroxyl, halo, an ester, an ether, a carboxylic acid group, a pharmaceutically acceptable salt of a carboxylic acid group, and --SR, in which R is hydrogen or an alkyl group, and Y is selected from the group consisting of oxygen, sulfur, C(OH), and C═O, and Z is selected from the group consisting of hydro and C(O)OR 1 , wherein R 1 is an alkyl, or a prodrug or pharmaceutically acceptable salt thereof, in an amount sufficient to treat said animal for choroidal neovascularization prophylactically or therapeutically.
Claim 3
Dependent Claim
20 words
The method of claim 1, wherein the halo group is selected from the group consisting of fluorine, chlorine and bromine.
Claim 4
Dependent Claim
15 words
The method of claim 1, wherein the ester is a C 1 -C 6 ester.
Claim 5
Dependent Claim
15 words
The method of claim 1, wherein the ether is a C 1 - 6 ether.
Claim 6
Dependent Claim
23 words
The method of claim 1, wherein said pharmaceutically acceptable salt of a carboxylic acid group is a sodium salt or a potassium salt.
Claim 7
Dependent Claim
28 words
The method of claim 1, wherein the alkyl groups are C 1 -C 6 alkyl groups and the alkoxy group is a C 1 -C 6 alkoxy group.
Claim 8
Dependent Claim
16 words
The method of claim 1, wherein said inhibitor of the protein tyrosine kinase pathway is genistein.
Claim 9
Dependent Claim
16 words
The method of claim 1, wherein said choroidal neovascularization is that which results from macular degeneration.
Claim 10
Dependent Claim
25 words
The method of claim 1, wherein said choroidal neovascularization is that which has been treated, is being treated or will be treated with laser photocoagulation.
Claim 11
Dependent Claim
25 words
The method of claim 1, wherein said choroidal neovascularization is that which has been treated, is being treated or will be treated with photodynamic therapy.
Claim 12
Dependent Claim
24 words
The method of claim 1, wherein said choroidal neovascularization is choroidal neovascularization that persists or recurs after surgical removal of an existing choroidal neovascularization.
Claim 13
Dependent Claim
15 words
The method of claim 1, wherein said choroidal neovascularization is that which results from histoplasmosis.
Claim 14
Dependent Claim
16 words
The method of claim 1, wherein said choroidal neovascularization is that which results from pathological myopia.
Claim 15
Dependent Claim
120 words
The method of claim 1, wherein said choroidal neovascularization is that which results from angioid streaks, anterior ischemic optic neuropathy, bacterial endocarditis, Best's disease, birdshot retinochoroidopathy, choroidal hemangioma, choroidal nevi, choroidal nonperfusion, choroidal osteomas, choroidal rupture, choroideremia, chronic retinal detachment, coloboma of the retina, Drusen, endogenous Candida endophthalmitis, extrapapillary hamartomas of the retinal pigmented epithelium, fundus flavimaculatus, idiopathic, macular hold, malignant melanoma, membranproliferative glomerulonephritis (type II), metallic intraocular foreign body, morning glory disc syndrome, multiple evanescent white-dot syndrome (MEWDS), neovascularization at ora serrata, operating microscope burn, optic nerve head pits, photocoagulation, punctate inner choroidopathy, radiation retinopathy, retinal cryoinjury, retinitis pigmentosa, retinochoroidal coloboma, rubella, sarcoidosis, serpoiginous or geographic choroiditis, subretinal fluid drainage, tilted disc syndrome, Taxoplasma retinochoroiditis, tuberculosis, or Vogt-Koyanagi-Harada syndrome.
Claim 16
Dependent Claim
16 words
The method of claim 10, wherein said choroidal neovascularization is that which results from macular degeneration.
Claim 17
Dependent Claim
10 words
The method of claim 15, wherein genistein is administered systemically.
Claim 18
Dependent Claim
20 words
The method of claim 16, wherein genistein is administered in an amount from about 1 mg/kg/day to about 100 mg/kg/day.
Claim 19
Dependent Claim
20 words
The method of claim 17, wherein genistein is administered in an amount from about 15 mg/kg/day to about 50 mg/kg/day.
Claim 20
Dependent Claim
13 words
The method of claim 16, wherein genistein is administered orally or by injection.
Claim 21
Dependent Claim
25 words
The method of claim 10, wherein said choroidal neovascularization is that which has been treated, is being treated or will be treated with laser photocoagulation.
Claim 22
Dependent Claim
17 words
The method of claim 20, wherein genistein is administered topically, subconjunctivally, retrobulbarly, periocularly, subretinally, suprachoroidally, or intraocularly.
Claim 23
Dependent Claim
16 words
The method of claim 21, wherein genistein is administered by a mechanical reservoir, device or implant.
Claim 24
Dependent Claim
23 words
The method of claim 21, wherein genistein is administered intraocularly in an amount from about 0.1 mg total to about 5 mg total.
Claim 25
Dependent Claim
23 words
The method of claim 23, wherein genistein is administered intraocularly in an amount from about 0.5 mg total to about 1 mg total.
Claim 26
Dependent Claim
17 words
The method of claim 10, wherein genistein is administered topically, subconjunctivally, retrobulbarly, periocularly, subretinally, suprachoroidally, or intraocularly.
Claim 27
Dependent Claim
16 words
The method of claim 25, wherein genistein is administered by a mechanical reservoir, device or implant.
Claim 28
Dependent Claim
23 words
The method of claim 25, wherein genistein is administered intraocularly in an amount from about 0.1 mg total to about 5 mg total.
Claim 29
Dependent Claim
23 words
The method of claim 27, wherein genistein is administered intraocularly in an amount from about 0.5 mg total to about 1 mg total.
Claim 30
Dependent Claim
24 words
The method of claim 10, wherein said choroidal neovascularization is choroidal neovascularization that persists or recurs after surgical removal of an existing choroidal neovascularization.
Claim 31
Dependent Claim
17 words
The method of claim 29, wherein genistein is administered topically, subconjunctivally, retrobulbarly, periocularly, subretinally, suprachoroidally, or intraocularly.
Claim 32
Dependent Claim
16 words
The method of claim 30, wherein genistein is administered by a mechanical reservoir, device or implant.
Claim 33
Dependent Claim
23 words
The method of claim 30, wherein genistein is administered intraocularly in an amount from about 0.1 mg total to about 5 mg total.
Claim 34
Dependent Claim
23 words
The method of claim 32, wherein genistein is administered intraocularly in an amount from about 0.5 mg total to about 1 mg total.
Claim 35
Dependent Claim
15 words
The method of claim 10, wherein said choroidal neovascularization is that which results from histoplasmosis.
Claim 36
Dependent Claim
16 words
The method of claim 10, wherein said choroidal neovascularization is that which results from pathological myopia.
Claim 37
Dependent Claim
120 words
The method of claim 10, wherein said choroidal neovascularization is that which results from angioid streaks, anterior ischemic optic neuropathy, bacterial endocarditis, Best's disease, birdshot retinochoroidopathy, choroidal hemangioma, choroidal nevi, choroidal nonperfusion, choroidal osteomas, choroidal rupture, choroideremia, chronic retinal detachment, coloboma of the retina, Drusen, endogenous Candida endophthalmitis, extrapapillary hamartomas of the retinal pigmented epithelium, fundus flavimaculatus, idiopathic, macular hold, malignant melanoma, membranproliferative glomerulonephritis (type II), metallic intraocular foreign body, morning glory disc syndrome, multiple evanescent white-dot syndrome (MEWDS), neovascularization at ora serrata, operating microscope burn, optic nerve head pits, photocoagulation, punctate inner choroidopathy, radiation retinopathy, retinal cryoinjury, retinitis pigmentosa, retinochoroidal coloboma, rubella, sarcoidosis, serpoiginous or geographic choroiditis, subretinal fluid drainage, tilted disc syndrome, Taxoplasma retinochoroiditis, tuberculosis, or Vogt-Koyanagi-Harada syndrome.
References Cited (Backward Citations)
US5637703A
Cited
WO1997030701A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-02-21 | 2003-08-23 | 2004-02-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-02-21 | 2007-08-23 | 2008-02-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-02-21 | 2011-08-23 | 2012-02-22 | $7700.00 | Window Closed / Lapsed |